Cargando…
Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer—The CONKO-008 Phase I Investigation
Background: Primary objective of this present trial was to define the maximum tolerable dose of lapatinib in combination with oxaliplatin, 5-fluorouracil, and folinic acid (OFF) in refractory pancreatic cancer. The secondary objective was to assess the safety and efficacy of lapatinib plus OFF. Meth...
Autores principales: | Striefler, Jana K., Stieler, Jens M., Neumann, Christopher C. M., Geisel, Dominik, Ghadjar, Pirus, Sinn, Marianne, Malinka, Thomas, Pratschke, Johann, Stintzing, Sebastian, Oettle, Helmut, Riess, Hanno, Pelzer, Uwe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409879/ https://www.ncbi.nlm.nih.gov/pubmed/36013144 http://dx.doi.org/10.3390/jcm11164905 |
Ejemplares similares
-
Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study
por: Striefler, Jana Käthe, et al.
Publicado: (2021) -
α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study
por: Sinn, M, et al.
Publicado: (2014) -
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
por: Riess, Hanno, et al.
Publicado: (2008) -
Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer – the CONKO 004 pilot trial
por: Pelzer, Uwe, et al.
Publicado: (2014) -
Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study
por: Pelzer, Uwe, et al.
Publicado: (2010)